Loading chat...
FL S1750
Bill
AI Summary
- Establishes state policy that Florida patients and third-party payers should not pay more for prescription drugs than prices available in international markets
- Requires prescription drug manufacturers to annually report international drug price data to the Agency for Health Care Administration beginning October 1, 2025, with noncompliance penalties of $10,000 per day for the first 30 days and permit suspension thereafter
- Directs the agency to contract with an entity to designate reference price source countries and establish reference prices for each prescribed drug, limited to countries with a real GDP per capita of at least 40% of the U.S. level and excluding countries with single-payer government price-setting systems
- Caps pharmacy charges for cash-paying patients and health insurer reimbursement for covered outpatient drugs at the established reference price, with savings required to be passed on through reduced policyholder cost sharing and premiums
- Requires the Office of Insurance Regulation and the Agency for Health Care Administration to submit a joint annual report to the Governor and Legislature beginning January 1, 2026, detailing savings, access barriers, market response, and program impact
Legislative Description
International Drug Reference Pricing
Last Action
Died in Health Policy
3/8/2024
Full Bill Text
No bill text available